# Efficacy and Safety of AM-111 as Acute Sudden Sensorineural Hearing Loss Treatment

> **NCT02809118** · PHASE3 · TERMINATED · sponsor: **Auris Medical, Inc.** · enrollment: 56 (actual)

## Conditions studied

- Hearing Loss, Idiopathic Sudden Sensorineural

## Interventions

- **DRUG:** AM-111 0.4 mg/ml
- **DRUG:** AM-111 0.8 mg/ml
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02809118
- **Lead sponsor:** Auris Medical, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-06
- **Primary completion:** 2018-02
- **Final completion:** 2018-02
- **Target enrollment:** 56 (ACTUAL)
- **Why stopped:** Availability of relevant new efficacy data from another study
- **Last updated:** 2020-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02809118

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02809118, "Efficacy and Safety of AM-111 as Acute Sudden Sensorineural Hearing Loss Treatment". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02809118. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*